Home / Innere Medizin / Onkologie / ESMO 2018: „Primären Prostatatumor zusätzlich bestrahlen, wenn Metastasenlast gering“
OA Priv.-Doz. Dr. Martin Marszalek

ESMO 2018: „Primären Prostatatumor zusätzlich bestrahlen, wenn Metastasenlast gering“

OA Priv.-Doz. Dr. Martin Marszalek, Abteilung für Urologie und Andrologie, SMZ Ost – Donauspital, Wien, bringt die Practice-Changing-Messages beim Prostatakarzinom auf den Punkt.

Abstracts

791O - Updated results of GETUG-12, a phase III trial of docetaxel-based
chemotherapy in high-risk localized prostate cancer, with a 12-year follow-up
K. Fizazi

LBA4 - Effects of Abiraterone Acetate plus Prednisone/Prednisolone in High and Low Risk Metastatic Hormone Sensitive Prostate Cancer
A. P. Hoyle

LBA30 - ERA 223: A phase 3 trial of radium-223 (Ra-223) in combination with
abiraterone acetate and prednisone/prednisolone for the treatment of
asymptomatic or mildly symptomatic chemotherapy-naïve patients (pts) with
bone-predominant metastatic castration-resistant prostate cancer (mCRPC)
M. Smith

LBA5_PR - Radiotherapy (RT) to the primary tumour for men with newly-diagnosed metastatic prostate cancer (PCa): Survival results from STAMPEDE (NCT00268476);
C. Parker

Quelle: ESMO 2018

LOGIN

Login

Passwort vergessen?